The stock price of Agios Pharmaceuticals fell sharply by over 20% after reports emerged of an unexpected side effect linked to its only marketed drug, Pyrukynd, in thalassemia patients. This news is critical for investors as it directly impacts the company's revenue potential and market confidence in its product.